Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant botulinum toxin type A - JHM Biopharma

Next Previous
Drug Profile

Recombinant botulinum toxin type A - JHM Biopharma

Alternative Names: Eveotox; JHM-03

Latest Information Update: 10 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JHM BioPharma (Tonghua)
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Antispastics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholinesterase inhibitors; Glutamate antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glabellar lines
  • Phase I/II Muscle spasticity

Most Recent Events

  • 23 Jul 2025 JHM BioPharma completes a phase I/II trial in Muscle spasticity in China (IM) (NCT06584240)
  • 30 Apr 2025 Phase-III clinical trials in Glabellar lines in China (IM) (NCT06937944)
  • 22 Apr 2025 JHM BioPharma plans a phase III trial for Glabellar lines in China in April 2025(IM) (NCT06937944)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top